We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Puma Biotechnology Inc | NASDAQ:PBYI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.14 | 3.84% | 3.79 | 3.78 | 3.82 | 3.79 | 3.60 | 3.62 | 37,510 | 14:58:22 |
From Jul 2023 to Jul 2024
By Sabela Ojea
Puma Biotechnology said the Food and Drug Administration granted orphan drug designation to its alisertib drug, aimed at treating small cell lung cancer, an aggressive of the disease.
The biopharmaceutical company said it is now working to begin the Phase II trial of alisertib.
Orphan drug designations are granted to drugs or biologics used for the treatment, prevention or diagnosis of a rare disease that affects less than 200,000 people in the U.S.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 21, 2023 16:40 ET (20:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Puma Biotechnology Chart |
1 Month Puma Biotechnology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
